Reducing particle size in the nano-range leads to a dramatic increase in the surface area available for solvation and an increase in the rate of dissolution for solid compounds. Particles in the nanoscale may also be more soluble because of changes to particle curvature and the introduction of defects into the crystal lattice. As a result, API nanocrystals may yield oral bioavailabilities that far exceed those obtained using conventional particles or micronized particles of poorly water-soluble compounds.

At Harpago, we utilize top-down particle size reduction processes, where larger particles are fragmented into smaller ones via wet milling.

Nanosuspensions provide a flexible approach to oral administration and can be used as liquid forms preclinically and early clinically. For late-phase or commercial use, nanosuspensions may be converted into solid forms after removal of water (for example via spray drying or bead layering) and subsequently processed into a capsule or a tablet formulation.